Segundo estudio de extensión abierto de 2 años de duración para evaluar la seguridad tolerabilidad y eficacia de canakinumab (ACZ885), un anticuerpo monoclonal anti-interleuquina-1?, en pacientes con artritis reumatoide activa - A2201E2 Segundo estudio de extensión abierto de 2 años de duración para evaluar la seguridad tolerabilidad y ...
Segundo estudio de extensión abierto de 2 años de duración para evaluar la seguridad tolerabilidad y eficacia de canakinumab (ACZ885), un anticuerpo monoclonal anti-interleuquina-1?, en pacientes con artritis reumatoide activa - A2201E2 Segundo estudio de extensión abierto de 2 años de duración para evaluar la seguridad tolerabilidad y ...
Product Name: ACZ885 Product Code: ACZ885 INN or Proposed INN: Canakinumab Other descriptive name: Recombinanthumanmonoclonalantibodytoinerleukin-1betaoftheIgG1-K-classProduct Name: ACZ885 Product Code: ACZ885 INN or Proposed INN: Canakinumab Other descriptive name: Reco ...
A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1ß monoclonalantibody in patients with active rheumatoid arthritis - A2201E2 A 2-year open-label second extension study toevaluate thesafety, tolerability and efficacy ofcanakin ...
A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1ß monoclonalantibody in patients with active rheumatoid arthritis - A2201E2 A 2-year open-label second extension study toevaluate thesafety, tolerability and efficacy ofcanakin ...
Product Name: ACZ885 Product Code: ACZ885 INN or Proposed INN: Canakinumab Other descriptive name: Recombinanthumanmonoclonalantibodytoinerleukin-1betaoftheIgG1-K-classProduct Name: ACZ885 Product Code: ACZ885 INN or Proposed INN: Canakinumab Other descriptive name: Reco ...
A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1ß monoclonalantibody in patients with active rheumatoid arthritis - A2201E2 A 2-year open-label second extension study toevaluate thesafety, tolerability and efficacy ofcanakin ...
A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1ß monoclonalantibody in patients with active rheumatoid arthritis - A2201E2 A 2-year open-label second extension study toevaluate thesafety, tolerability and efficacy ofcanakin ...
Product Name: ACZ885 Product Code: ACZ885 INN or Proposed INN: Canakinumab Other descriptive name: Recombinanthumanmonoclonalantibodytoinerleukin-1betaoftheIgG1-K-classProduct Name: ACZ885 Product Code: ACZ885 INN or Proposed INN: Canakinumab Other descriptive name: Reco ...